Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (Apadamtase Alfa /Cinaxadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA for the treatment of cTTP for individuals 12 years of age and older.